Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jasbir Dhaliwal

Physical Medicine & Rehabilitation Sanford, NC Medical Doctor

NPI 1609039692 CMS profile 380134

1303 Carthage St, Sanford, NC 27330

Open in the dashboard

General payments

$23,138

700 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jasbir Dhaliwal of Sanford, NC is reported in the CMS Open Payments database as having received $23,138 across 700 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,411 46
2024 General $2,699 56
2023 General $1,940 59
2022 General $3,310 128
2021 General $6,833 192
2020 General $4,270 128
2019 General $2,675 91

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jasbir Dhaliwal
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Jasbir Dhaliwal were reported at $1,411. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Jasbir Dhaliwal Physical Medicine & Rehabilitation median Middle half National median
2019 $2,675 $133 $45–$390 $163
2020 $4,270 $88 $29–$272 $114
2021 $6,833 $116 $33–$360 $132
2022 $3,310 $123 $40–$378 $149
2023 $1,940 $131 $43–$396 $160
2024 $2,699 $141 $45–$409 $164
2025 $1,411 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $17,281 460 payments
  2. Boston Scientific Corporation $1,065 22 payments
  3. Collegium Pharmaceutical, Inc. $1,010 49 payments
  4. Nevro Corp. $481 11 payments
  5. AbbVie, Inc. $454 20 payments
  6. SI-BONE, Inc. $361 8 payments
  7. Arbor Pharmaceuticals, Inc. $278 15 payments
  8. Scilex Pharmaceuticals Inc. $267 13 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $251 14 payments
  10. ASSERTIO THERAPEUTICS, Inc. $163 15 payments
  11. Other $1,527 73 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,138 700 payments
Products named General payments · program years 2019–2025
  1. Proclaim IPG $5,717 158 payments
  2. Proclaim Family of SCS IPGs $4,703 125 payments
  3. PROCLAIM Neuromodulation $3,517 120 payments
  4. PROCLAIM Neuromodulation $1,179 15 payments
  5. ETERNA Neuromodulation $827 13 payments
  6. ETERNA Structural Heart $665 18 payments
  7. BELBUCA $538 25 payments
  8. SPECTRA WAVEWRITER $495 8 payments
  9. XTAMPZA $419 21 payments
  10. UBRELVY $325 13 payments
  11. Other $5,673 252 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

482

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$22,851

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

32%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 24 $14,350
Morphine Sulfate Er Morphine Sulfate Brand 18 $2,692
Tramadol Hcl Er Tramadol Hcl Brand 23 $1,333
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 54 $1,166
Gabapentin Generic 78 $770
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 35 $522
Meloxicam Generic 74 $366
Pregabalin Generic 25 $300
Baclofen Generic 20 $289
Tramadol Hcl Generic 39 $214

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$336,115

Of which drugs: $18,327

Medicare patients

395

Average age 72

Services billed

9,998

244 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Depression 34%
Ischemic heart disease 30%
Heart failure 26%
Chronic kidney disease 25%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 205 3,075 $2,327
Injection, ketorolac tromethamine, per 15 mg J1885 Office 136 1,024 $494
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 24 54 $5

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XTAMPZA
$88 — —
UBRELVY
$66 — —
BELBUCA
$65 24 —
QULIPTA
$62 — —
Qutenza
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

700 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record